• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Secondary syphilis occurring under anti-CD20 therapy: risks, progression and approach.

作者信息

Garbers Luiz Augusto Fabricio de Melo, Haes Tissiana Marques de, Silva Souza Cacilda da

机构信息

Department of Internal Medicine, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.

Department of Neurosciences and Behavioral Sciences, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.

出版信息

An Bras Dermatol. 2024 Jul-Aug;99(4):632-634. doi: 10.1016/j.abd.2023.07.006. Epub 2024 Apr 12.

DOI:10.1016/j.abd.2023.07.006
PMID:38614937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11221156/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6734/11221156/6638910aa6d7/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6734/11221156/992ce8370aca/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6734/11221156/c0ae7bf5d299/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6734/11221156/6638910aa6d7/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6734/11221156/992ce8370aca/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6734/11221156/c0ae7bf5d299/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6734/11221156/6638910aa6d7/gr3.jpg

相似文献

1
Secondary syphilis occurring under anti-CD20 therapy: risks, progression and approach.抗CD20治疗下发生的二期梅毒：风险、进展及处理方法
An Bras Dermatol. 2024 Jul-Aug;99(4):632-634. doi: 10.1016/j.abd.2023.07.006. Epub 2024 Apr 12.
2
Secondary syphilis occurring under anti-TNFalpha therapy.TNFα 治疗后发生的二期梅毒。
Joint Bone Spine. 2010 Jul;77(4):364-5. doi: 10.1016/j.jbspin.2010.02.023. Epub 2010 May 8.
3
Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.继发性抗体缺乏症：抗 CD20 治疗神经炎症的并发症。
J Neurol. 2018 May;265(5):1115-1122. doi: 10.1007/s00415-018-8812-0. Epub 2018 Mar 6.
4
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.未接受过抗 CD20 为基础的生物治疗的滤泡性淋巴瘤患者的风险分层的生物标志物。
Am J Surg Pathol. 2021 Mar 1;45(3):384-393. doi: 10.1097/PAS.0000000000001609.
5
Serological diagnosis of secondary syphilis in a Rituximab-treated patient: an emerging diagnostic challenge?利妥昔单抗治疗患者继发性梅毒的血清学诊断：一个新出现的诊断挑战？
J Eur Acad Dermatol Venereol. 2021 May;35(5):e350-e352. doi: 10.1111/jdv.17126. Epub 2021 Feb 5.
6
[Active recurrent secondary syphilis: reactivation or reinfection?].[活动性复发性二期梅毒：复发还是再感染？]
Dermatologica. 1982 Nov;165(5):414-8.
7
Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.人源化或嵌合型抗 CD20 单克隆抗体治疗儿童肾病综合征：一项优效性随机临床试验。
J Am Soc Nephrol. 2021 Oct;32(10):2652-2663. doi: 10.1681/ASN.2021040561. Epub 2021 Sep 20.
8
Unusual manifestations of secondary syphilis occurring after orthotopic liver transplantation.原位肝移植后发生的二期梅毒的不寻常表现。
Am J Med. 1983 Jul;75(1):166-70. doi: 10.1016/0002-9343(83)91183-x.
9
Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20 B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis.新型抗 CD20 单克隆抗体与利妥昔单抗用于 CD20 B 细胞非霍奇金淋巴瘤诱导治疗的疗效和安全性：系统评价和荟萃分析。
Sci Rep. 2021 Feb 5;11(1):3255. doi: 10.1038/s41598-021-82841-w.
10
Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.退伍军人健康管理局的乙肝检测以及抗CD20抗体给药治疗。
World J Gastroenterol. 2016 May 21;22(19):4732-40. doi: 10.3748/wjg.v22.i19.4732.

本文引用的文献

1
Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD.接受奥瑞珠单抗或利妥昔单抗治疗多发性硬化症和视神经脊髓炎谱系疾病患者低丙种球蛋白血症和严重感染的预测因素。
J Neuroimmunol. 2023 Apr 15;377:578066. doi: 10.1016/j.jneuroim.2023.578066. Epub 2023 Mar 8.
2
The Great Imitator: Latent Neurosyphilis Revealed After Initiation of the Immunosuppressive Drug Secukinumab.模仿大师：在开始使用免疫抑制药物司库奇尤单抗后发现潜伏性神经梅毒。
Cureus. 2021 Oct 3;13(10):e18462. doi: 10.7759/cureus.18462. eCollection 2021 Oct.
3
Serological diagnosis of secondary syphilis in a Rituximab-treated patient: an emerging diagnostic challenge?
利妥昔单抗治疗患者继发性梅毒的血清学诊断：一个新出现的诊断挑战？
J Eur Acad Dermatol Venereol. 2021 May;35(5):e350-e352. doi: 10.1111/jdv.17126. Epub 2021 Feb 5.
4
Malignant Syphilis in a Young Patient With Juvenile Idiopathic Arthritis Under Biological Therapy.一名接受生物治疗的幼年特发性关节炎年轻患者的恶性梅毒
J Clin Rheumatol. 2021 Dec 1;27(8S):S382-S383. doi: 10.1097/RHU.0000000000001495.
5
A rare case of malignant syphilis after adalimumab therapy due to Crohn's disease associated with bariatric surgery.一例克罗恩病相关减重手术后接受阿达木单抗治疗后发生的罕见恶性梅毒病例。
Diagn Microbiol Infect Dis. 2019 Sep;95(1):89-92. doi: 10.1016/j.diagmicrobio.2019.04.009. Epub 2019 Jun 21.
6
Syphilis in the Setting of Anti-tumor Necrosis Factor Alpha Therapy.抗肿瘤坏死因子α治疗背景下的梅毒
Reumatol Clin (Engl Ed). 2019 Nov-Dec;15(6):e108-e110. doi: 10.1016/j.reuma.2017.12.008. Epub 2018 Feb 3.
7
Secondary syphilis infection under treatment with ustekinumab.在用优特克单抗治疗的二期梅毒感染
Clin Exp Dermatol. 2017 Oct;42(7):836-838. doi: 10.1111/ced.13189. Epub 2017 Sep 3.
8
Re-emergence of syphilis in the biological era.梅毒在生物学时代的再度出现。
Int J Dermatol. 2016 Dec;55(12):e626-e628. doi: 10.1111/ijd.13389. Epub 2016 Aug 6.